335 related articles for article (PubMed ID: 32350552)
61. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
62. miRNome profiling in Duchenne muscular dystrophy; identification of asymptomatic and manifesting female carriers.
Mousa NO; Sayed AA; Fahmy N; Elzayat MG; Bakry U; Abdellatif A; Zahra WK; Osman A
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34472584
[TBL] [Abstract][Full Text] [Related]
63. DMDtoolkit: a tool for visualizing the mutated dystrophin protein and predicting the clinical severity in DMD.
Zhou J; Xin J; Niu Y; Wu S
BMC Bioinformatics; 2017 Feb; 18(1):87. PubMed ID: 28152980
[TBL] [Abstract][Full Text] [Related]
64. Giovanni Nigro and the Naples's school: historical contribution to the knowledge of heart involvement in Duchenne/Becker muscular dystrophies.
Politano L
Acta Myol; 2020 Dec; 39(4):187-190. PubMed ID: 33458573
[TBL] [Abstract][Full Text] [Related]
65. Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides.
Bertoni C
Front Biosci; 2008 Jan; 13():517-27. PubMed ID: 17981565
[TBL] [Abstract][Full Text] [Related]
66. Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.
Seto JT; Ramos JN; Muir L; Chamberlain JS; Odom GL
Curr Gene Ther; 2012 Jun; 12(3):139-51. PubMed ID: 22533379
[TBL] [Abstract][Full Text] [Related]
67. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
Relizani K; Goyenvalle A
Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
[TBL] [Abstract][Full Text] [Related]
68. Duchenne Muscular Dystrophy: From Diagnosis to Therapy.
Falzarano MS; Scotton C; Passarelli C; Ferlini A
Molecules; 2015 Oct; 20(10):18168-84. PubMed ID: 26457695
[TBL] [Abstract][Full Text] [Related]
69. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Aslesh T; Erkut E; Yokota T
Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
[No Abstract] [Full Text] [Related]
70. High-Throughput Digital Image Analysis Reveals Distinct Patterns of Dystrophin Expression in Dystrophinopathy Patients.
Torelli S; Scaglioni D; Sardone V; Ellis MJ; Domingos J; Jones A; Feng L; Chambers D; Eastwood DM; Leturcq F; Yaou RB; Urtizberea A; Sabouraud P; Barnerias C; Stojkovic T; Ricci E; Beuvin M; Bonne G; Sewry CA; Willis T; Kulshrestha R; Tasca G; Phadke R; Morgan JE; Muntoni F
J Neuropathol Exp Neurol; 2021 Oct; 80(10):955-965. PubMed ID: 34498054
[TBL] [Abstract][Full Text] [Related]
71. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
72. Screening for antisense modulation of dystrophin pre-mRNA splicing.
Dickson G; Hill V; Graham IR
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S67-70. PubMed ID: 12206799
[TBL] [Abstract][Full Text] [Related]
73. DMD transcript imbalance determines dystrophin levels.
Spitali P; van den Bergen JC; Verhaart IE; Wokke B; Janson AA; van den Eijnde R; den Dunnen JT; Laros JF; Verschuuren JJ; 't Hoen PA; Aartsma-Rus A
FASEB J; 2013 Dec; 27(12):4909-16. PubMed ID: 23975932
[TBL] [Abstract][Full Text] [Related]
74. [From gene to disease; the dystrophin gene involved in Duchenne and Becker muscular dystrophy].
den Dunnen JT; de Visser M; Bakker E
Ned Tijdschr Geneeskd; 2002 Feb; 146(8):364-7. PubMed ID: 11887623
[TBL] [Abstract][Full Text] [Related]
75. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
Wein N; Alfano L; Flanigan KM
Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
[TBL] [Abstract][Full Text] [Related]
76. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol.
Romero NB; Benveniste O; Payan C; Braun S; Squiban P; Herson S; Fardeau M
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S45-8. PubMed ID: 12206794
[TBL] [Abstract][Full Text] [Related]
77. A review on mechanistic insights into structure and function of dystrophin protein in pathophysiology and therapeutic targeting of Duchenne muscular dystrophy.
Elasbali AM; Al-Soud WA; Anwar S; Alhassan HH; Adnan M; Hassan MI
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130544. PubMed ID: 38428778
[TBL] [Abstract][Full Text] [Related]
78. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
79. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies.
Spitali P; Hettne K; Tsonaka R; Charrout M; van den Bergen J; Koeks Z; Kan HE; Hooijmans MT; Roos A; Straub V; Muntoni F; Al-Khalili-Szigyarto C; Koel-Simmelink MJA; Teunissen CE; Lochmüller H; Niks EH; Aartsma-Rus A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):715-726. PubMed ID: 29682908
[TBL] [Abstract][Full Text] [Related]
80. Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy.
Matsuo M
Brain Dev; 1996; 18(3):167-72. PubMed ID: 8836495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
